相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting Heat-Shock Protein 90 Improves Efficacy of Rapamycin in a Model of Hepatocellular Carcinoma in Mice
Sven A. Lang et al.
HEPATOLOGY (2009)
Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells
Matthew M. Roforth et al.
ANTI-CANCER DRUGS (2008)
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A. Rizzieri et al.
CLINICAL CANCER RESEARCH (2008)
Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
Bing-Hua Jiang et al.
DRUG RESISTANCE UPDATES (2008)
Challenges in developing targeted therapy for pancreatic adenocarcinoma
Devalingam Mahalingam et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex
Bruno D. Fonseca et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Gene expression profiling in sarcomas
Katharina Tschoep et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Identification of Protor as a novel Rictor-binding component of mTOR complex-2
Laura R. Pearce et al.
BIOCHEMICAL JOURNAL (2007)
The proline-rich akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1
Noriko Oshiro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding
Lifu Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zhihong Zeng et al.
BLOOD (2007)
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Yasemin Sancak et al.
MOLECULAR CELL (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Emilie Vander Haar et al.
NATURE CELL BIOLOGY (2007)
Disrupting insulin-like growth factor signaling as a potential cancer therapy
Deepali Sachdev et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma
Lanie K. Francis et al.
CLINICAL CANCER RESEARCH (2006)
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s
Maria A. Frias et al.
CURRENT BIOLOGY (2006)
The epidermal growth factor receptor pathway: A model for targeted therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2006)
mTOR and cancer: insights into a complex relationship
David M. Sabatini
NATURE REVIEWS CANCER (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis
Li Ma et al.
CELL (2006)
Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin
G Ohji et al.
JOURNAL OF BIOCHEMISTRY (2006)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events
MK Holz et al.
CELL (2005)
Mammalian target of rapamycin as a therapeutic target in leukemia
FJ Giles et al.
CURRENT MOLECULAR MEDICINE (2005)
Molecular organization of target of rapamycin complex 2
S Wullschleger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The coordinate regulation of the p53 and rnTOR pathways in cells
ZH Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival
PS Hammerman et al.
BLOOD (2005)
Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis
L Ma et al.
CELL (2005)
The serine/threonine kinase pim-1
M Bachmann et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
eIF4E - from translation to transformation
Y Mamane et al.
ONCOGENE (2004)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
HG Wendel et al.
NATURE (2004)
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group
A Bamias et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Raptor, a binding partner of target of rapamycin
K Yonezawa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
SH Um et al.
NATURE (2004)
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov et al.
CURRENT BIOLOGY (2004)
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E
DC Fingar et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E Jacinto et al.
NATURE CELL BIOLOGY (2004)
The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif
H Nojima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR
DH Kim et al.
MOLECULAR CELL (2003)
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy
JY Blay et al.
EUROPEAN JOURNAL OF CANCER (2003)
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
R Loewith et al.
MOLECULAR CELL (2002)
Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling
XS Gao et al.
NATURE CELL BIOLOGY (2002)
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
K Hara et al.
CELL (2002)
MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery
DH Kim et al.
CELL (2002)
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
M Van Glabbeke et al.
EUROPEAN JOURNAL OF CANCER (2002)
IGF-I receptor signalling in transformation and differentiation
B Valentinis et al.
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2001)
TOR, a central controller of cell growth
T Schmelzle et al.
CELL (2000)
Role of the insulin-like growth factor family in cancer development and progression
H Yu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Understanding Ras: 'it ain't over 'til it's over'
JM Shields et al.
TRENDS IN CELL BIOLOGY (2000)
PTEN mutations in endometrial carcinomas: A molecular and clinicopathologic analysis of 38 cases
E Bussaglia et al.
HUMAN PATHOLOGY (2000)
分享论文
